retatrutide grey market Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Grey Market GLP-1 Trends and
Description
Do you have other health conditions that affect your metabolism
[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Alvarez E, Martnez MD, Roncero I, Chowen JA, Garca-Cuartero B, Gispert JD, et al

The tradeoff: retatrutide appeared to show higher rates of nausea (42.4%), diarrhea (32.0%), and vomiting (25.3%) than tirzepatide or orforglipron at their top doses

This medications ability to address multiple aspects of metabolism and appetite control makes it particularly effective for patients who have found traditional weight loss methods challenging

10.1016/j.survophthal.2023.07.002
